WSE’s Pick of the Week: BioSyent

BioSyent’s Oral Science acquisition helped lift quarterly revenue 95%. Ahead of its Planet MicroCap Toronto presentation, investors are watching integration, margins and the balance between further growth and shareholder returns.

BioSyent (TSX Venture: RX) has nearly doubled quarterly sales following its expansion into oral health. The next test is sustaining that growth while protecting profitability.

President and CEO René Goehrum will present at Planet MicroCap Toronto on Wednesday, October 28, at 11:30 a.m. EDT, with investor meetings available October 28–29. The appearance gives investors an opportunity to question management about its acquisition strategy and the performance of its enlarged business.

The Canadian specialty healthcare company acquires or licenses developed products, then markets and distributes them through healthcare channels. Its portfolio includes FeraMAX oral iron supplements, while the March acquisition of Oral Science expanded its reach into dental hygiene and oral-health products.

Second-quarter revenue rose 95% to C$19.87 million, including C$8.22 million from the new oral-health segment in its first full quarter under BioSyent. The existing pharmaceutical business also grew, with sales increasing 14% to C$11.11 million. Net income after tax climbed 41% to C$2.85 million.

A bigger business brings a different margin mix

Oral Science has added meaningful revenue, but its products carry lower gross margins than BioSyent’s pharmaceutical portfolio. Consolidated EBITDA margin fell to 25% from 27% a year earlier. Acquisition-related amortization also weighed on net profitability.

Competition remains another pressure point. BioSyent reported increased activity in Canada’s oral iron market, where it continues to support FeraMAX through healthcare-professional outreach and consumer marketing. International pharmaceutical sales increased sharply, although a large individual shipment helped drive that performance. Repeat orders will matter when assessing the durability of that growth.

BioSyent ended June with C$8.94 million in cash, cash equivalents and short-term investments, compared with C$28.65 million at year-end following its acquisition spending. It also repurchased 218,500 shares during the first half and paid quarterly dividends of C$0.055 per share. Those commitments put capital allocation alongside integration as a key management question.

BioSyent offers exposure to an established healthcare commercialization business with existing revenue and profits. Its enlarged portfolio creates room for growth, while the changing margin mix makes cash generation and earnings quality especially important.

What we’re watching: Oral Science’s contribution after integration costs settle, FeraMAX’s performance against competitors, repeat international orders, and management’s balance between acquisitions, dividends and buybacks. The October 28 presentation provides the next opportunity for an update.

This feature is editorial research, not an investment recommendation.